Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 11, 2007

Transgene and Roche Tackle HPV-Mediated Diseases in Deal Worth Over Euro 218M

  • Roche and Transgene entered into an exclusive, worldwide collaboration agreement to develop and commercialize products from Transgene's therapeutic vaccine program against HPV-mediated diseases.

    The agreement includes Transgene's lead candidate, TG 4001, for the treat ment of high-grade cervical intraepithelial neoplasia (CIN2/3). Under the agreement, Roche will lead worldwide development and commercialization. TG 4001 has completed Phase II studies and is in the planning-stage to enter into Phase III studies.

    Transgene will receive Euro 13 million as an upfront payment and Euro 10 million as a near-term regulatory milestone payment related to planning the Phase III studies.

    Roche may pay Transgene up to Euro 195 million upon the achievement of certain further development and sales-based events in various HPV-related indications. Transgene is also entitled to double-digit escalating royalties on sales once a product is marketed.

    Roche will hold all manufacturing rights but has agreed to allocate, on commercial terms, exclusive responsibility to Transgene for the clinical-trial supply of TG 4001 and additional HPV products, which may be developed in the future. This agreement will be extended to commercial-supply manufacturing for an initial period.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »